BioSpace News Archive

Corporation Terranueva (CSE : TEQ) ) (the “ Corporation ” or “ Terranueva ”), one of the 6 companies in Québec holding a licence from Health Canada to develop cannabis products for medical and recreational purposes, is pleased to announce that Economic Development Canada (“ ED C ”) has granted a loan of $500,000 to the business to support its day-to-day operations. This assistance from EDC comes from the Regional Relief and Recovery F

Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) and the Menarini Group today announced an update on the elacestrant Phase 3 EMERALD trial.

Sept. 24, 2020 20:01 UTC Marinus has satisfied the FDA’s protocol-specific questions for the Phase 3 trial in refractory status epilepticus (RSE) Company intends to begin enrollment for registrational Phase 3 clinical trial in RSE; over 55 out of projected 80 sites have been selected for trial participation Noted clinical expert in status epilepticus, Henri Vaitkevicius, M.D., has been appointed Vice President, Clinical Development

Athletico’s performance score in national physical therapy benchmark reflects on-going commitment to delivering best in class patient outcomes

Medtronic plc (the “Company”) (NYSE: MDT) announced today that its wholly-owned subsidiary, Medtronic Global Holdings S.C.A. (“Medtronic Luxco”), has priced an offering (the “Offering”) of €1,250,000,000 principal amount of 0.000% senior notes due 2023, €1,000,000,000 principal amount of 0.000% senior notes due 2025, €1,000,000,000 prin

Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform, ImmTOR TM , today announced that Selecta’s Chief Executive Officer, Carsten Brunn, Ph.D., will participate virtually in the following investor conferences in October: Jefferies Virtual Gene Therapy/Editing Summit Date: Thursday, October 1, 2020 Fireside chat

Today, Maryland Governor Larry Hogan and Dr. Michelle McMurry-Heath, President & CEO of Biotechnology Innovation Organization (BIO), joined Novavax President & CEO Stanley Erck to discuss the importance of the biotechnology sector in Maryland, the industry’s efforts to address COVID-19, and progress being made by Novavax to develop a vaccine for the deadly virus.

Opdivo (nivolumab) Significantly Improves Disease Free-Survival vs. Placebo as Adjuvant Therapy for Patients with High-Risk, Muscle-Invasive Urothelial Carcinoma in Phase 3 CheckMate -274 Trial In an interim analysis, CheckMate -274 met primary endpoints of disease-free survival in both all randomized patients and in patients whose tumor cells express PD-L1 ≥1% Opdivo has now demonstrated clinically meaningful efficacy in the adjuvant treatment of

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on September 11, 2020, the Compensation Committee of the Board of Directors approved “inducement” grants to 30 new employees under Rule 5635(c)(4) of the NASDAQ Marketplace Rules. The option grants entitle employees, in aggregate, to purchase up to 173,000 shares of common stock and receive

Community Health Centers and the nearly 30 million patients they serve have a temporary reprieve from a new regulation implementing the President’s Executive Order around insulin and EpiPens. The Office of Management and Budget (OMB) has revised the regulation from an Interim Final Rule to a Proposed Rule, signaling that the pub